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The clinks1 and ekctmpbyslologic predictors of ruwfsht anti- 
nrrhytixoir drug therap> for paden& with indueibtc vrntrkutar 
tschycardia were evslunted in 59 conweutiw patients undergoing 
seriat ekctmpharmacol~k trials. Structural heart dose was 
lcsr frquently present in patients for whom efftrtive therapy was 
hwnd ,p < O.O$!. The presence of coronary artery disew end a 
history of prior mywardiat infarction uere riyificpntly more 
irqurntly present m o.atknk for whom nntisrrbythmir drug 
lhernpy could not be louad (p < 0.05). The corrected QT interval 
and ventricular effeetbe refractory period measured at a pacing 
cyek kngth of Ooo R’I we stgntfknntty shorter in rnpondon 
comosred with nonrrrwnders tOTiatrrvat41+ 52 versus 460 d . - 
59 nIli Ye”!rn’-“tar effectt”. refrattwy pried 237 * 28 YIrsU 
254 + 14 10% tp c 0.051. In addition. the lnterebtrogram 
coupling interval of the ventriculsr extrastimulus initiating yen., 
trkutsr taehyeardit HIS signilkantlj shorter in roponden corn. 
pared vi,h nmrwpondrn ,223 f 37 versus 251 t 33 ms; p = 
o.w3,. 
Lo&tie regrmion ansly& kknti6ed a shwt vtntrkmlar inter- 
rkctroeram CouDllne inlrrval (0 < 0.011 aed alKern of DdW 
myc&dlat inf&ltt fp < omi a5 the only indepcsdmt pi&c. 
tars of antisrrhythmk dna nppnrska of the indtibn of 
venthular iierekctmgram eoupiini interval. 
Thus, brulii electr@ayzMqk --ts identify pa. 
titnlS with inducible ventrkutar uehyeardii rho are ttket7 to 
r-d to sntbrrhythmtc drug therapy. Furttwmwe, these 
patients demoostr~tr grater drupinduwd ckctrapbysiologk 
changu. 
,J Am Cd Cdhl1991;17.914-20) 
Suppression of the induction of ventricular lachyarrhyth- 
miss by antiarrhythmic drug% during serial electropharmaco- 
logic tri& is associated with a favorable patient ctutcorne 
1121. Previous studio of baseline factors predicting rubre- 
~oeot imtiarrhythmis drug efficacy have focused on clinical 
charxterislic% A higher probability of identifying successful 
anriarrhythmic drug therapy by serial electropharmacologic 
r!udies has been reported 13-S) for patients of young age and 
femolc gender who have no orramc heart direaie or signifi- 
cant left ventricular dysfunction. A luwcr probability of 
identifying an effective drug therapy a been associated 
with the presence of Ggoificonl com~ry artery disease. 
previous Q wave myocardial infarclion or left ventr~ular 
aneurysm 0.4). The only previously reported (4) baseline 
ekctrophysiologic determinants of antiarrhythmic drug inef- 
ficacy are an HV interval >@I ms or ventricular tachycardia 
induction with a single ventricular extrastimulus. Bavline 
electrophysiologic predictors of drug efficacy have not pre- 
viously been reported. FunheroIore. the effects 01 anliar- 
rhythmic drugs on elecrrophysiologic measurer ar predictors 
of cffeciive therapy have not been extensively studied. 
We recently observed 16) that ventricular functional re- 
fractoriness war a more important determinant of ventricular 
tnchycardia induction than was ventricular effective refrac- 
toriness. We therefore postulated that antiarrbythmic drug 
elects on vcmricular functional refractoriness might be 
important determinants of antiarrhythmic dmg efficacy. Ac- 
cordingly. the purpose ofthc present study was to assess the 
relative importance of baseline clinical and electrophysio- 
logic characteristics and changer in ventricular refractari- 
ness associated with antiarrhylhmic drug elcacy. 
Methods 
study patients. The study group consisled of 59 comet- 
ulive patients with indwble ventricular tachynrrhythmias 
who underwent serial electropharmacoloic trials for the 
treatment of symptomatic ventricular tachgarrhylhmias. 
There were 53 men and 6 women wth a mean age (*SD) of 
61 2 IO years (range 28 to 78). The most common cardiac 
diagnosis war coronary arter, diseare: 48 of 50 patients with 
this diagnosis had a history of pnor myocardtal mfarctmn 
Dilated cardiomyopathy was present in five patients and oo 
structural heart disease could be identified in four pattents. 
The indications for eleetrophy~iolqic study were veotricu- 
lar fibrillation in I2 patient, and sustained ventricular tachy- 
cardia in 37. Teen patients presented with hypotcnstvc ‘~yotp 
totns (ryncope in nine) and spmttaneou~ nonwtained 
ventricular tachycardia documented at another ume. None 
of these patients had previously undergone an mvawe 
electrophysiologis evaluation. 
Eketroptysicdogie study. Patient, underwent electro- 
physiologic evaluation in the postabsarplive state afwr in- 
formed wrttten consent we, obtained. The studies were 
approved by Be Conjoint Medical Ethics Committee of the 
Faculty of Medicine. Universtty of Calgary. All antiarrhyth- 
mic drugs including beta.adrencceptor blocking agents were 
discontinued for at least live drug half-liver before study. 
Two oaapolar electrode cathelen were pattioned m the 
right ventricle: one at the right ventricular apex and o,,c at 
the right ventricular outflow tract. Stimuli 2 mr m duraion 
with an intensity twice the diastolic threshold were applied 
to the right ventricular apex. Single. double and triple 
ventricular extmstimuli were admwstered after eight beat 
trains of ventricular pacing at cycle :sneths of 6tH. SW and 
400 mr. Thereafter. 4 and i5 beet w&of rapid ventricular 
pacing were applied. beginning at a cycle lengh of 300 ox. 
The cycle length was decreased by 10 mr in!erv& until 2: t 
ventricular capturewar observed. If ventricular tachycardia 
was not repmducihiy induced. the stimulation gr~tocol was 
repeated from the right venhicular outflow tract. At baseline 
study. the end paint of ventricular stimulation was complr- 
tion of the protocol or induction of suained ventricular 
tachycardia. Reproducibility wa% den nrtrated by the m- 
duction of ventricular tachycardla at least twice. Catheters 
were reinrened for eech subsequent electropharmacolog~c 
trial and stimulation was applied to the site used at bawline 
dudy to induce ventricular tachycardia (71. 
EI=twbwmaml@c studies. Oral antiarrhytbmlc drug 
therapy wa> initiated on completion of the initial drup-free 
electmphysiologic study. Antiarrhythmic drugs were Felled 
until an e&ctive therapy was identified or a minimal series 
of drug trials had been evaluated. Pharmacologic therapies 
included trials of at least one class IA agent turually qum- 
dine or procainamide). the combination of a class IA and 
class IB agent luwally quinidinelmcxil~rincl. aclaw IC agnt 
(usually pmpafenone) and a class III agent lusually sotaloll. 
Other drugs such a\ beta-adremxeptor blocker,, calcium 
channel blockers or the mvestxalional drug amilortde (8) 
were less frequently employed. When an et&live pharma- 
cologic therapy was not identified. patients were treated uitb 
empiric amiodarone thempy. surgical therapy or implanta- 
tion of an automatic cardmvertcr-dehbrillator. 
Itinitionr. Ventricular twhycardia was defined as five 
or more consecutive ventricular complexes at a rate 
> I20 beatslmin and was considered sustained when it per- 
slated br 230 I or required premature termination becats; 
of hemodynamic collapse. Therapy was considered effective 
d no more than four consecutive ventricular beats could be 
induced on completion ofthe entire electrophysiologic study 
protocol. The venlricular effective refractory period was the 
lon&e~t interamtdus coupling interval that failed to capture 
the ventricle.. The ventricular functional refractory period 
wab the minimal interval between ventricular electrogramr 
measured uring ventricular extrastimulation. The interstim- 
ulus coupling interval inducing ventricular tachycardia was 
the inlerval between the last two pacing stimuli inducing 
txhycardia. For example. if rentricular tachycardia was 
induced by the introduction of a third ventricular extrastim- 
uIu( ($1. the mterrtimu!ur coupling interval measured was 
the S,S, interval initiating ventricular tachycardia. Like- 
ww. the ventricular electrogram Gmxval inducing ventric- 
ular tachycardn was defined as the intexal between the last 
IWO evoked ventricular rerponszs initiating ventricular 
tachycardia. Ven:ricular conduction time war estimated as 
the interval between the right ventricular apex and outflow 
tract electrogramr. 
Data analysis. The clinical variables tested as univariate 
predIctorb of respane to oral antiarrbythmic drug therapy 
were age. Ecnder. etiology of heart disease. history of prior 
myocardial infarction. location of myocardial infarction. 
history oi cardiac arrest, history of congestive heart failure. 
left ventricular ejection fraction and number of episodes. 
hosp%dzaIionr and cardiovenionr for documented ventric- 
ular tachyarrhythmias before eleetmphysiologic study. The 
electrophyvologic variables tested as univariate predictors 
of re\ponw to oral antiarrhythmic drug therapy were RR 
interval. PR interval. QRS duration, corrected QT (QTc) 
interval. AH interval. HV interval. ventrictdar effective and 
functional refractory periods. surface QRS duration and 
right ~cntrtcular conduction time of the shortes: single 
ventricular extrastimulus that depolarized the ventricles, 
cycle length and configuration of induced ventricular tachy- 
cardia. number of extrastimuli required for ventricular 
tachycardia mdwtion. interstimulus coupling iitterwl induc- 
ing ventrndar tachycardia and ventricular r-lectrogram in- 
terval inducing ventricular tachycardia. Continuous data are 
presented ar mean values 2 SD. Unpaired data were com- 
pared by tuo-tailed I test for continuous variabler and by 
chl-square analysis for comparisons of proportions. Univmi- 
ate predictorr with a p value <O.lO were identified and 
stepwi5e lopi\tic regression analysis was applied (9). 
Ur6elinline dintcat predtttors of wpomx to antiarrhythmie 
drug therapy tTabk 1). These 59 patients underwent IS7 
elecrropharmncologic trials. Effective drug therapy was 
identified for 26 patients (responders) who underwent 2.0 + 
1.7 drug trial\ and \\a> not identified for 33 padcot\ ~ooore- 
spondcrs) uho undcrwen~ 4.1 r 1.4 drug triill\ ,p ,z U.001,. 
The two group, did not diiicr with respcc, 10 dpe. There 
tended I” he more men amon% rc\ponderr IYf,%) than amung 
nonrc~pondcrs 182%) Ip = U.0871. Coronary anery disease 
Ip = 0.0251 and history of prior myocardial infwctmn tp - 
O.WSl were more prevalcn~ in the nonre~ponder~. Fifteen 
percent of rcrpandcra had no underlying hew dware. 
whereus all nonresponden had structural heart disease tp = 
0.02). Left ven~riculx ejection fraclion lcnded 10 be lower 
among nonre\ponders (p = 0.0631. ‘The incidcncc of clinicaal 
heart fadure. number of empiric antizrrhythmic drug trial5 
before electropbyriologic evaluation. presenting arrhythmia 
or history of rudden cardiac dealh dui ntit differ berrrecn the 
IWO group,. Thus. the univaridte clinical predictors of re- 
sponw to antiarrhythmic therapy were lcfi vcmricular ejec- 
tion fraction 20.30. male gender and abarnce of prior 
myocardlnl infarctloo. coronary artery dircae or rtruclural 
hesrl disease. 
Ikeline eleclrophysiologic predictors of rerpona to anti- 
arrbthmic drw therapr (Table 21. Fifwfive oatienl\ 193%) 
had &wined &r&l& whycdrdia o; fibriliadon induced 
~1 the baseline eluclruphysioloeic wdy. The induced or- 
rhythmias were wlained manomorpb~c ~entr~ul~r why- 
cardia m 51 p;ltwnts. venwicular tibrdletion or plcomorphic 
venlr~culilr tachycardia wilh iti cycle length <2W on m 4 and 
nonsustained ventricular ldchycardw in 4. The durafion of 
non>ustamcd vcnlriculsr tachycardia ranged frum 7 to I5 
complexes. There arrhythmia\ were induced by the applica- 
tion ofonc e*traumuIu~ in 8 palw~lr. Iwo chlrwimuli in 2X 
pauem\ and three extraslimuli in 23 pawnts. Ventncular 
arrhylhmiw were mu mduoed by the application of vmlric- 
ular bur>l pacing. Re\panden and nanresponders bad simi- 
lar RR. PR. QRS. AH and HV intervals measured during the 
brselinc eleclrophy~ielog~c bludy. However. responders bad 
B ~ignilicantly \horwr QTc interval lhan did nonresponders 
Ip = 0.0321. 
Ventricular tachycardia cycle length, type of arrhythmia 
induced and number of exlrastimuli required for ventricular 
lachyarrhythmia induction did nor differ significantly be- 
seen groups. However. Ihc imerslimulus coupliog intervai 
tp < 0.01, and ventricular elecuogram inwrval (p < 0.003) 
1ha1 mduced Ihe vcntriculdr tachyarrhylhmia were shorter in 
responders than in nonresponders. 
pacing cycle lengths are ihown in Figure I. The venwicular 
effecwe refractory period measured at a pacing cycle length 
of 40U III\ WI> \ignificanlly rhurter in responders than in 
nunresponder, 1237 f 2X vers”s 254 f 24 ms: p = 0.023l. 
The ventricular funcllonal refrxtory period measured at this 
pacing cycle length also tended to be shorter in responders 
(25Y z 23 verw 27U f 24 ms: p = O.O?4l. Significant 
dilrencr, in ventricuk : tfractorinws were not observed at 
pacing cycle lenglbr of bw and 5110 ms. although these 
wlues were shoncr I” Ihe respwders. 
Drug-induced chaw*l:s in electrophysiolugic measurements 
as prfdictors al respme lo anliarrhylhmir drug therapy. 
Thz eLcts of antiarrh lhmic drug. therapy on the ventricular 
elec~ropram terval ~r,lucing vcnlriculdr tachycardia during 
baseline study in responders and nonrerponders are cam- 
pared in Figure 2. For nonre~ponder~. the trealment wmnc- 
ular electrogram inlerval mducmg vanncular tachycardw 
was obtained from lhe lint electropharmacologic trial. For 
responders. who b) definition had no treatment ventncular 
electrogram inlerval mducing venlncular lach+ardra. the 
mmmul trealment venlricular eleclroglam interval-that 
cuuld be ubraincd by venuicular extra~timulus testing. Nev- 
ertheler\. a ~ignificanlly greater increase m the shortest 
venlr~cular clectrogram coupling interval was obxrved in 
rcrpunden during elkctive amiarrhythmic drug :‘xrdpy 
compared wrh that in nonresponden during [heir firs1 mef- 
lecrwe elecwophysiolopc study. 
Ven~ncular effective and functional refractory p&ads 
durmg the effective drug trial in the responders were corn- 
pared wlh those obraincd dunnc the first drua lrial in Ihe 
nonrc\pondcrs. These did not d&r 4gnificantiy. However. 
the changcb m ventricular ekctive and funclional refrdckxy 
period, accompanying drug therapy were Ggnificanrly 
greater in rqwnden than nonresponders (Fig. 3). No big- 
Figure 3. Change, 1b.1 I” len,rlF”lar efecuve l”ERP, and fwc- 
,ional WFRP) rcfrx~ury perk& a.rcaa,cd ulth anliarrhythmic 
dmg lhrrapy I” rc\ponderr ,RI and nonrnpondcrr (NRI a, three 
drive cycle ten@hs ,DCL,: Wu. 5W and 4M1 mr. (iwaler changes I” 
vemriculrr ctkdvr and iunctional refractory peri& wxc ob. 
scrvrd I” wpondcrs compared wilh nunrespondcrr I’p c 0.08. 
*p < 0.05. “,I < U.“,l. 
niticant dilkrcnce~ m QRS dw&m or ventricuhr cocduc- 
lion time of premature cxtrastimub were observed uhcn 
comparing ,hc two groups IFig. 4). 
Simihrr kl,~ rhrwpiur wcw ewdrmrrtl 08 Oolh r~~pwrdcri 
cmd nonrcrpowfrrr. Quinidine or quioidinelmexili,ine com- 
bination was cRec,ive therapy for 69% of responden. Tbsre 
agents were also the imtial ,h<rapy cvalua,ed in 13% of 
nonresponders. Quinidinc serum levels measured at the time 
of ihc clectrophysiologic study were simdu. in responders 
(IO.1 f 2.6 ,M3.3 t 0.8 p@mll and nunrczponder~ 19.7 i 
2.5 uM13.1 r 0.8 ueimtt. 
~uttivariate p&&s of response to serial drug testing. 
Skpwise logrstic reprersiun analysis identified two veriables 
as significant independent predictw of an,iarrhy,hm,c drug 
response: Q shon fr?30 mst venrricular ele~trogrdm interval 
inducing veI)!ricuIar tachycardia tp < ll.01) and the absence 
of prior myocardial infarction tp < 0.051. Twenty responders 
could be identified by a ,hun ventricular elcctrogram in!er- 
vat inducing ventricular lachycardw Four addi:ional re- 
sponder\ were identified bv absence of prior mvocardial 
ikfarctmn (Fig. 5. upper pkell. The bkeline vemricular 
etTective refwrory petiud measured at a 400 ms pacmg cycle 
length iz also shown for each responder and nonrcsponder in 
Figure 5 llower panell. This variable did not discriminate 
between responders and nonresponders as highly a, did ,he 
ven,ricuku clec,rogram inlewd inducing ventricular !achy- 
cardia. 
FiRurr 4. Cha”ge5 101 I” QRS dunrian and vemrw,8r canduuion 
lime ,!X of ventncutar cx,ra~,~mut~ awaated wi,h amiarrby,hme 
irug thrmpy in rc\ponderi ,R, and nonresponders ,NR, were 
slmiiar a, ,hree dnve cycle lengths IDCL): b(x). Xl0 and 4w ms. 
Major finding 01 the E(udy. The presen, rludy examined 
clinical and ek,rophyrialogic predictors of response to 
antiarrhylhmic drug therapy in patienfs with ventricular 
txhyarrbythmias undergmng serial etectrophwmacologic 
,r&. One major finding of lhis prospeclive study is the 
powerful independent correlation of a shon ven,riculsr 
elec,roEram imerval indwcing ventricular tzchycardia a, 
baseline 5,,,dy and the probability of subsequent response to 
oral antiarrhythmic drug thcrdpy as assessed by electrophys- 
iologic studies. This elecirophyriologic variable was rhe 
single ma, powerful indepcnden, predictor of response to 
antiarrhytbmic drug therapy. The second major finding of 
this study is tha, et?eaive antiarrhylhmic drug therapy was 
associated Gth greater increases in et&live and funcrional 
wwicular refractory periods than was ineffective therapy. 
Basetine clinical predictors of rospome to antiarrhythmic 
drug therapy. Previous studies 13-5) have focused on clini- 
cal faclors. Absence of s,ruc,ural hear, disease. absence of 
coronary heari disease including myocardial infarcdon and 
welt preserved left ventricular function have uniformly been 
predictors of responre to amiarrhythmic drug. The prenen, 
results are m agrcemen, with ,hae findings. Other factors 
assuciated with drug response in some hu, no, all studies 
include female gender (31. young age 13.41 and iewer epi- 
scdes of ventricular tachycardia 13) or previous ineffecwe 
empiric antiarrhythmic drug trials (3). Our analysis does no, 
confirm these less frequemly reponed asscxiafions 
3.0 
E 
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wrsmems has no, been previously reponed. Dilferences in 
1) pathologic wbaate between drug responders and nonre- 
.$ .wo * 
. \ponder* mlghl account for the differencea in elechophysi- 
. 
B 1 ologlc meawremmrr observed in our study. Nanresponders 
:Q . ;..A rended to have a lower ejection fraction and remote myocar- =a- 
* : - B 200~ 
dral mfarcliun. Previous human sedies have demonstrated a 
; ;- ** 
;:A longer vcmr~ular refractory permd in the setting of conger- 
1 p*o 
. ..I tive hearl fanlure i10) or atherosclerotic heart disease t I I). 
rr : ::* These changes may also. in part. be mediated by changes in 
5 :o 
:: +.t t* 
autonomic nervous system function (1% klowever. we did 
not observe a s~gmficant difference in heart raw at resl 
IBO - 
i::* 1 
between Ihe two groups 10 suggert rha[ autonomic lone at 
R NR re,, ddTercd 
Drug-induced cbmws Ln eMropbysio@ie measurements 
340 
1 as predictors of rqmse to anliarrhythn~k drug therapy. Prevmu4y reported (5.!3-151 drug-induced changes in elec- f a 
308 - 
trophywluglc meaburemenls predicting response 10 antiar- 
: rhylhmlc drug therapy include suppression of ventricular 
f 
S= 
;:A whyarrhythmia inducibilily and greater ventricular effec- tt 
g g pea $ I.. we refractory period prolong&on after intravenous pro- :..* cainamide admmistration. We also observed a grcatcr drug- 
;::* ;;: 
mduced prolongation of ventricular &cLive and functional 
220 - L. refractory periods in those who responded to a variety of 
.f oral antiarrhythmic agents during long-term therapy. Fur- 
. thermore. the present study demonstrates a sign&ant asso- 
180- * w&n belueen drug-induced prolongalion of minimal yena 
R NR wic&r clectrogram intervals during appbcation of multiple 
ven~rtculx extrastimuli and drug efficacy. The mechanism or 
Figure 5. Upper pami, Ventricular elecwouam intervals IV,V) lhrt 
initialed ventricular tachycard~a (VT1 dwmg the ba4me chc1ro~ 
mecham~m$ of tbew greater drug-induced effects observed 
physiologic study are rhown for responders (RI and nonresponder> m responder\ 15 unknown. We did not observe signiiicant 
,NR,. Twenty of 26 responders had a V-V ,n,crval ~230 m\ ddTercnce> between reqxmders and nonresponders in the 
compared wth only IO of 33 nonresponders had a shon V-V wum concentrations of the anriarrhythmic drugs used in 
interval. OpRl symbds indicate pdlients wthoul a hisrory of prior thn inve\tigalion. However. differences in myocardial drug 
myocardiil infarction. The presence qfcilheroflhese two vsnables 
correcdy ndent&ed 24 of 26 responden and their abrrnce correc!I) 
dlwburlon or pharmacodynamics might be important fac- 
idenlilcd 22 of 33 nonresponderr. Lower panel. Bwlme ventncular 
ton. Becaux nonresponders tended to have more sewre 
eflective refractory penod (VERPI measured a~ drire cycle length left vemr~cular dyrfunction. higher levels of circulat;ng 
400 mr is shown for raponderr and nanresponder?. Srveaeen of 25 caecholammo might have limiled drug-induced increases in 
resoonders bad a vemricular effective refrxlorv period ~24” m, vcntriculilr refraorirvx (161. 
c&pared with only 13of31 nonroponder% The pr&enceofa rhsn 
ventricular effectwe refmclory pcriad and no hntory of prmr 
mymrdi?! i;!fxclion lapra gmhals) corrcclly idenlified onl) 19 01 
25 rerponderr and their absence correcll~ ~demhcd 17 uf 31 
nonrqmndert. 
Baseline ekclrophyriolagic predictors of rqmnse 10 anti- 
arhythmic drug therapy. The presenl wdy focused on 
electmphysmlogic predictors of req-ion~e 10 aniiarrhythmlc 
drug therapy. Previous studies (?-?I hvc not emphasired 
elecrrophysiologic predictor, and none of the reported pre- 
dstors have been consistent findings. Several baselme elec- 
troohyGoloeic measuremenls were ascocmled wlh response 
Clinical implications. This study demonsrrales that anal- 
yva ol clectrophyriologic variables in addition 10 clinical 
vanable\ can be used 10 ldenufy patients with recwrenl 
rcntricular tachycardia or IibFillation who are likely to 
benefit from serial electropharmacologic trials. Abhougb 
werdl faclor\ were univariate predictors of posilive re- 
,ponre to drug therapy. only &vu factors were identified to 
he independent prediclorc of such response: a short venrric- 
ular electrogram interval inducing ventricular lachycardia 
and abwnce of previous myocardial infarction. These data 
may be valuable m the early ~lratificalion of patients to serial 
elecvopharmacologic rludies or implantation of an anti- 
tichvcardia pacemakerldefibrillator. Furthermore. observed 
10 &xrh~hm!c drug therapy m the preaenl study. ihere d&encea in aniiarrhythmic drug elTecls on ventricular 
mclude shon Qfc interval. hhort elTective refracmry penod refraclonness may indicate a difference in electrophysiologic 
and shon interstimulus and vcntr~culareleclrogr~m coupling substrate between responders and nonrelponders. 
intcrval~ initiating ventncuhx rachyarrhyrhmra The pwtive Conclusions. This investigation focused on the electro- 
predictive value of whew bitxhne eleclrophysiologic mea- phy4olognc characleriaticr that distinguish patients with 
venlnculsr whyarrhylhmrar who respond t” drug therapy 
from Ihow who do not. Drug respondrn had it shorter 
b&me venlricular refractory period and greater drug- 
mduced prolongation of refractory pods lhan did nonre- 
spnders. turthcr ,tudn are required 10 identify the mech- 
anirms UnderlyIng the% dxtTercnce\. 
